ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Authors:
Open Access
- 16 January 2015
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (3) , 324-330
Abstract
We studied 1696 patients (18 to 61 years) with acute myeloid leukemia for ASXL1 mutations and identified these mutations in 103 (6.1%) patients. ASXL1 mutations were associated with older age (PP=0.041), secondary acute myeloid leukemia (PPPASXL1 mutations occurred in all cytogenetic risk-groups; normal karyotype (40%), other intermediate-risk cytogenetics (26%), high-risk (24%) and low-risk (10%) cytogenetics. ASXL1 mutations were associated with RUNX1 (PIDH2R140 mutations (P=0.007), whereas there was an inverse correlation with NPM1 (PFLT3-ITD (P=0.0002), and DNMT3A (P=0.02) mutations. Patients with ASXL1 mutations had a lower complete remission rate (56% versus 74%; P=0.0002), and both inferior event-free survival (at 5 years: 15.9% versus 29.0%; P=0.02) and overall survival (at 5 years: 30.3% versus 45.7%; P=0.0004) compared to patients with wildtype ASXL1. In multivariable analyses, ASXL1 and RUNX1 mutation as a single variable did not have a significant impact on prognosis. However, we observed a significant interaction (P=0.04) for these mutations, in that patients with the genotype ASXL1mutated/RUNX1mutated had a higher risk of death (hazard ratio 1.8) compared to patients without this genotype. ASXL1 mutation, particularly in the context of a coexisting RUNX1 mutation, constitutes a strong adverse prognostic factor in acute myeloid leukemia.Keywords
This publication has 33 references indexed in Scilit:
- Loss of Asxl1 leads to myelodysplastic syndrome–like disease in miceBlood, 2014
- The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigeneticsLeukemia, 2012
- ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcomeLeukemia, 2012
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene RepressionCancer Cell, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseasesJournal of Hematology & Oncology, 2012
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic valueHaematologica, 2011
- Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutationsBlood, 2010
- A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11Gene, 2003